In Vivo Therapy with M2e-Specific IgG Selects for an Influenza A Virus Mutant with Delayed Matrix Protein 2 Expression-Reference-Cited by-同舟云学术

In Vivo Therapy with M2e-Specific IgG Selects for an Influenza A Virus Mutant with Delayed Matrix Protein 2 Expression

Published:2021-08-31 Issue:4 Volume:12 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Van den Hoecke Silvie¹²,Ballegeer Marlies¹²³,Vrancken Bram⁴^ORCID,Deng Lei¹²,Job Emma R.¹²³,Roose Kenny¹²³,Schepens Bert¹²³,Van Hoecke Lien²⁵,Lemey Philippe⁴,Saelens Xavier¹²³^ORCID

Affiliation:

1. VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium

2. Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium

3. Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium

4. KU Leuven—University of Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Leuven, Belgium

5. VIB-UGent Center for Inflammation Research, VIB, Ghent, Belgium

Abstract

Broadly protective influenza vaccine candidates may have a higher barrier to immune evasion compared to conventional influenza vaccines. We used Illumina MiSeq deep sequence analysis to study the mutational patterns in A/Puerto Rico/8/34 viruses that evolve in chronically infected SCID mice that were treated with different M2e-specific MAbs.

Funder

Fonds Wetenschappelijk Onderzoek

FP7 People: Marie-Curie Actions

China Sate Scholarship

Interuniversity Attraction Projects

Virogenesis

Horizon 2020

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link